Amicus (FOLD) AI Stock Analysis

• Market Cap: $3.02B
• Dividend Yield: N/A
• Average Volume (3M): 4.88M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: 21.28%
• EPS Growth: 87.30%
• Country: US
• Employees: 499
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 308,533,540
• 10 Day Avg. Volume: 4,715,829
• 30 Day Avg. Volume: 4,884,967
• PEG Ratio: 0.79
• Price to Book (P/B): 14.78
• Price to Sales (P/S): 5.43
• P/FCF Ratio: -76.57
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 4.38
• Enterprise Value/Gross Profit: 4.90
• Enterprise Value/Ebitda: 44.29
• 1Y Price Target: $15.88
• Price Target Upside: 62.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): $629.16M

• Rating: 64 Neutral
• Price Target: $10.50 ▲(7.14% Upside)

Amicus Therapeutics shows strong technical momentum and positive earnings call sentiment, indicating potential for growth. However, financial performance challenges and valuation concerns weigh on the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth reflects strong market demand and effective commercialization of therapies, supporting long-term business expansion.

Product Performance

Strong performance of key products like Galafold indicates successful market penetration and patient adoption, enhancing revenue stability.

Global Market Expansion

Expanding global market presence through new reimbursement agreements strengthens competitive position and revenue potential.

Negative Factors

High Leverage

High leverage increases financial risk, potentially limiting flexibility and increasing vulnerability to economic downturns.

Cash Flow Challenges

Negative cash flow growth indicates potential liquidity issues, which could impact the ability to fund operations and growth initiatives.

Profitability Volatility

Inconsistent profitability suggests potential challenges in achieving stable financial performance, affecting investor confidence.

Amicus Business Overview & Revenue Model

Company Description

Amicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing advanced therapies for rare and orphan diseases, particularly those caused by enzyme deficiencies. The company specializes in the research, development, and commercialization of innovative treatments for conditions such as Fabry disease and Pompe disease. Amicus leverages its proprietary platforms, including its biologics and small molecule drug discovery capabilities, to create novel therapies that enhance patient outcomes.

How the Company Makes Money

Amicus generates revenue primarily through the commercialization of its approved therapies, such as Galafold (migalastat), which is designed to treat Fabry disease. The company also earns revenue through collaborations and licensing agreements with larger pharmaceutical firms, which may involve upfront payments, milestone payments, and royalties on product sales. Additionally, Amicus may receive funding from government grants or research contracts aimed at supporting the development of its pipeline products. Strategic partnerships with other biopharmaceutical companies can further enhance its revenue streams by providing shared resources and expanding market access for its therapies.

Amicus Financial Statement Overview

Summary

Amicus shows strong revenue growth and gross profit margins, but low net profit margins and high leverage pose financial risks. Cash flow challenges are evident, though free cash flow covers net income.

Income Statement

Amicus has shown a positive trend in revenue growth with a 4.82% increase in the TTM period. The gross profit margin remains strong at approximately 89.77%, indicating efficient cost management. However, the net profit margin is relatively low at 3.32%, suggesting limited profitability. The EBIT and EBITDA margins are modest, reflecting operational challenges.

Balance Sheet

The company has a high debt-to-equity ratio of 1.92, indicating significant leverage, which could pose financial risks. Return on equity is positive at 9.67%, showing some profitability for shareholders. The equity ratio is moderate, suggesting a balanced asset structure but with potential risk due to high debt levels.

Cash Flow

Amicus's free cash flow growth is negative, indicating cash flow challenges. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting income to cash. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow covers net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	598.70M	528.29M	399.36M	329.23M	305.51M	260.89M
Gross Profit	535.61M	475.35M	362.03M	290.63M	271.05M	229.84M
EBITDA	59.27M	29.39M	-92.08M	-199.58M	-202.87M	-242.98M
Net Income	-14.06M	-56.11M	-151.58M	-236.57M	-250.46M	-276.85M
Balance Sheet
Total Assets	868.81M	785.03M	777.88M	724.17M	905.14M	886.52M
Cash, Cash Equivalents and Short-Term Investments	263.84M	249.95M	286.20M	293.60M	482.50M	483.27M
Total Debt	442.82M	443.64M	445.06M	452.12M	440.13M	441.73M
Total Liabilities	638.39M	590.99M	617.71M	601.12M	597.77M	600.14M
Stockholders Equity	230.42M	194.04M	160.17M	123.05M	307.37M	286.38M
Cash Flow
Free Cash Flow	9.69M	-37.44M	-76.53M	-170.34M	-206.38M	-236.52M
Operating Cash Flow	12.98M	-33.89M	-69.09M	-166.57M	-202.49M	-233.29M
Investing Cash Flow	-60.33M	-560.00K	98.06M	92.32M	78.76M	-13.58M
Financing Cash Flow	-12.32M	5.12M	61.68M	-7.46M	212.07M	262.86M

Amicus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOLD, the sentiment is Positive. The current price of 9.8 is above the 20-day moving average (MA) of 9.43, above the 50-day MA of 8.79, and above the 200-day MA of 7.58, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 63.34 is Neutral, neither overbought nor oversold. The STOCH value of 49.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOLD.

Amicus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	80 Outperform	$2.79B	13.24	27.52%	―	25.56%	44.42%
FOLD	64 Neutral	$3.02B	―	-6.87%	―	21.28%	87.30%
TVTX	55 Neutral	$3.15B	―	-410.78%	―	114.22%	77.02%
OCUL	53 Neutral	$2.49B	―	-81.83%	―	-9.21%	-8.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMVT	45 Neutral	$3.99B	―	-95.93%	―	―	-27.70%
IRON	43 Neutral	$3.46B	―	-34.78%	―	―	-34.96%

Amicus Corporate Events

Amicus Therapeutics’ Pompe Disease Study: A Potential Game-Changer for Investors

Amicus Therapeutics is currently recruiting for a global, prospective observational registry study titled ‘A Global Prospective Observational Registry of Patients With Pompe Disease.’ The study aims to evaluate the long-term safety, effectiveness, and impact on quality of life of treatments for Pompe disease, including both treated and untreated patients. This research is significant as it seeks to enhance understanding of the disease’s natural history and treatment outcomes.

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer

Amicus Therapeutics is conducting a global, prospective observational registry study titled ‘A Global Prospective Observational Registry of Patients With Pompe Disease.’ The study aims to evaluate the long-term safety and effectiveness of treatments for Pompe disease, assess their impact on quality of life, and describe the natural history of untreated Pompe disease. This research is significant as it provides real-world data on patient outcomes.

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer

Amicus Therapeutics is conducting a global observational study titled ‘A Global Prospective Observational Registry of Patients With Pompe Disease.’ The study aims to evaluate the long-term safety and effectiveness of treatments for Pompe disease, including their impact on quality of life and patient-reported outcomes. It also seeks to document the natural history of untreated Pompe disease.